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Economic evaluation of newborn hearing screening:
modelling costs and outcomes
Gesundheitsökonomische Evaluation von Neugeborenen-Hörscreening:
Modellierung von Kosten und medizinischer Wirksamkeit
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Objectives: The prevalence of newborn hearing disorders is 1-3 per
1,000. Crucial for later outcome are correct diagnosis and effective
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outcome, costs, and cost-effectiveness extracted. A Markov model was
designed to calculate cost-effectiveness ratios.
Results: Economic data were extracted from 20 relevant publications
out of 39 publications found. In the model total costs for screening of 2 School of Medicine, Ludwig-
Maximilians University
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100,000 newborns with a time horizon of ten years were calculated:
2.0 Mio.€ for universal screening (U), 1.0 Mio.€ for risk screening (R),
and 0.6 Mio.€ for no screening (N). The costs per child detected: 3 InstituteforSocialPediatrics,
Ludwig-MaximiliansUniversity
Munich, Germany
13,395€ (U) respectively 6,715€ (R), and 4,125€ (N). At 6 months of
life the following percentages of cases are detected: U 72%, R 43%, N
13%. 4 Harvard Center for Risk
Analysis, Boston, USA Conclusions: A remarkable small number of economic publications
mainly of low methodological quality was found. In our own model we
foundreasonablecost-effectivenessratiosalsoforuniversalscreening.
Considering the outcome advantages of higher numbers of detected
cases a universal newborn hearing screening is recommended.
Zusammenfassung
Einleitung: Die Prävalenz von Hörstörungen bei Neugeborenen beträgt
1-3 pro 1000 Neugeborene. Entscheidend für die spätere Entwicklung
der betroffenen Kinder sind möglichst frühzeitige Diagnose und Thera-
pie. Mit BERA und TEOAE stehen risikoarme Methoden zur Frühentde-
ckung zur Verfügung. Obwohl ein universelles Screening empfohlen
wird, wurde es in den meisten europäischen Ländern bisher nicht ver-
wirklicht.
Ziel des Projektes war es, die wissenschaftliche Evidenz von Neugebo-
renen-HörscreeningzuuntersuchenunddiemedizinischenFolgensowie
die Kosten verschiedener Programme zu vergleichen. Dabei wurden
diedreiverschiedenenScreening-StrategienuniversellesScreening(U),
Risiko-Screening(R)undkeinsystematischesScreening(N)verglichen.
Methoden: In einem interdisziplinären Health Technology Assessment
Projekt wurden alle relevanten, im Rahmen einer standardisierten
ausführlichenLiteraturrechercheidentifiziertenStudienzuNeugebore-
nen-HörscreeningeingeschlossenunddieErgebnissezurmedizinischen
Wirksamkeit, zu Kosten und zur Kosteneffektivität extrahiert. Um die
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Markov Modell entwickelt.
Ergebnisse: Aus 20 von insgesamt 39 Studien wurden ökonomische
Daten ausgewertet. Im Modell wurden Gesamtkosten für eine Kohorte
von 100.000 Neugeborenen in Höhe von 2,0 Mio.€ für ein universelles
Screening, von 1,0 Mio.€ für Risiko-Screening und 0,6 Mio.€ für die
Situation ohne systematisches Screening kalkuliert. Die Kosten pro
entdecktem Fall betrugen 13.395€ (U), 6.715€ (R) bzw. 4.125€ (N).
Bis zum Alter von 6 Monaten wurden 72% (U), 43% (R) bzw. 13% (N)
der Fälle entdeckt.
Schlussfolgerung:EswurdeeinebemerkenswertgeringeAnzahlgesund-
heitsökonomischer Studien von überwiegend mangelhafter methodi-
scher Qualität gefunden. Unser Modell konnte eine akzeptable Kosten-
effektivitäts-Relation auch für eine universelle Hörscreening-Strategie
zeigen, so dass in Anbetracht der höheren Zahl rechtzeitig entdeckter
Fälle auch aus ökonomischen Gesichtspunkten die Empfehlung für ein
universelles Screening auf konnatale Hörstörungen ausgesprochen
wird.
Introduction
According to calculations of the WHO world-wide approxi-
mately 350 Mio. people have hearing disorders. The
overall prevalence of connatal hearing disorders is 1-3
in 1,000 newborns, the prevalence in risk groups is es-
timated at about 10 times higher. Risk factors are e.g.
early child birth, infection in early pregnancy or family
history of hearing disorders [1]. For a detailed overview
of the medical and epidemiological background it is re-
ferred to the full version of the German HTA-report [2] or
the preceding British and French reports on NHS [3], [4].
Theneurologicaldevelopmentofhearingabilitiesrequires
anacousticstimulationassoonaspossible,latestbefore
finishing the first two years of life. Deficits due to absent
acousticstimulationduringthefirstyearsoflifearenearly
impossibletoimprovebylaterrehabilitation[5].Therefore
diagnosis and treatment as early as possible are neces-
sary for a successful and effective treatment of connatal
peripheral hearing disorders.
If connatal hearing disorders are detected and treated
in time, most of the children are enabled to pass through
a nearly normal development of speech and no special
education is necessary [6], [7], [5]. For the detection of
hearing disorders with TEOAE (transient evoked oto-
acoustic emissions) and BERA (brainstem evoked re-
sponse audiometry) tests with an acceptable sensitivity
and specificity are available. TEOAE is easier to perform,
lesstimeconsuming,andcheaper,butshowsmorefalse
positiveresults.BERArequiresmoretime,butisregarded
as the gold standard for the diagnosis of hearing dis-
orders. Although for screening purposes several auto-
mated versions of BERA are available, most of the pro-
grammes are using TEOAE.
Usual treatment of connatal sensory hearing disorders
consists of supply with hearing aids. If treatment with
hearing aids do not improve hearing, cochlea implants
should be considered.
Themeanageofdiagnosisofconnatalhearingdisorders
in Germany, like in most other western countries, is 2-4
years of age depending on the severity of hearing
impairment. Treatment is started on average 9 months
later[8],[9],[10].Thereisamarkeddiscrepancybetween
these findings and the recommendation of international
consensus groups.
Recommendations of the European Consensus Develop-
ment Conference on Neonatal Hearing Screening [11],
[12] are: diagnosis in the first 6 months of life and treat-
ment in the first 12 months of life. More recent recom-
mendationsoftheJointCommitteeonInfantHearingand
theDeutscheGesellschaftfürPhoniatrieundPädaudiolo-
gie [13], [14] even claim a detection at 3 months and
treatment in the first 6 months. To achieve an early dia-
gnosis and treatment, a universal screening for hearing
disorders is recommended. But a regular screening of
newbornsisneitherimplementedinGermanynorinmost
otherhealthcaresystems.Inthelastyearsseveralregion-
al newborn hearing screening programmes were imple-
mented in Germany [for example [15], [16], although
there is no regular reimbursement of the screening tests
by German statutory sickness funds.
Different tests or test combinations of BERA and TEOAE
are available. At present one of the most common
strategies is a so-called two-step TEOAE-strategy with a
singleTEOAEtestinthefirstdaysoflifeand,ifnoTEOAEs
are detected, a second similar test a few days later. If the
first or second test is negative the children are classified
astestnegative.Ifthefirstandthesecondtestispositive
the tested newborns are classified as test positive.
The objectives of this interdisciplinary economic health
technology assessment project were to compare the
costs,effectsandcost-effectivenessratiosofthreediffer-
ent strategies:
1. Universal screening of all hospital born newborns
2. Risk screening of all hospital born newborns with risk
factors
3. No regular screening
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1. Costs per screened child
2. Costs per case detected (case defined as hearing loss
>40dB on better ear)
3. Costs per case detected in time (in time defined as in
the first 6 months of life)
Methods
According to the methodological recommendation for
health technology assessment projects in Germany [17],
cost and cost-outcome calculations based on published
literature data combined with actual item costs were
performed. An externally reviewed literature search for
publications on newborn hearing screening from 1990
to September 2001 of relevant electronic databases
Medline, Embase, Evidence based Medicine, Healthstar,
Current Contents, DARE, NEED, Cochrane Library, ERIC,
PsycLIT, PsycINFO, INSPEC, and SOMED was performed.
If costs or cost calculations were mentioned in the title,
abstract or keywords, publications were included in the
economic part of the report. "Gray literature" like confer-
ence booklets, relevant internet homepages or publica-
tions not listed in literature databases was scanned by
hand. A detailed description of the literature search
strategy is documented in the full version of the report
[2] and can be obtained from the authors on request.
Detectedpublicationswerescoredaccordingtoanestab-
lished standardized questionnaire [2] and included re-
spectively excluded for further evaluation. Data from in-
cluded studies were converted to € using the purchasing
power parities (PPPs) of the Organization for Economic
Co-operationandDevelopment(OECD)andstandardized
to the year 1999 according to the German health sector
specific inflation rates given by the Federal Statistical
OfficeGermany (Statistisches Bundesamt Deutschland).
Overall nearly 800 publications dealing with hearing
screening were found. For the numbers of economic
publications please see result section.
Cost Calculations
As possibly relevant cost components were defined:
Direct medical costs:
• Costs for the implementation of the screening pro-
gramme
• Costs for screening tests
• Costs for the organization of the screening programme
• Costs for tracking
• Costs for further diagnostic procedures to detect (true
and false) screening positives
• Treatment for detected cases of hearing disorder
•• Regular controls
•• Treatment with hearing aids (supply, controls, batter-
ies etc.)
••Treatmentwithcochlearimplants(pre-operativetests,
device, operation procedure, rehabilitation)
Direct non-medical costs:
• Transportation costs for diagnostic procedures and
treatment
• Additional education costs for special institutions for
children with hearing disorders
Indirect costs:
• Work time loss for parents
• Work time loss for adults with hearing disorders
• Income loss due to hearing disorders
• Productivity loss due to premature mortality
Markov Model
Toestimatethelong-timecostsandoutcomesofnewborn
hearing screening a Markov model [18] was designed.
Markov models in medical decision analysis are con-
sideredasexplicitandquantifyingapproachfordecisions
between alternatives under uncertainty. The decision is
made according to the trade off between medical risks,
benefits and costs. As all models Markov models are not
able to reflect all aspects of clinical reality, but the most
relevant structures and parameters are demonstrated
and offered for discussion.
For design and calculation of the Markov model the
software DATA Treeage was used. The literature search
was extended to publications dealing with direct or indir-
ect costs of hearing disorders, costs, cost-effectiveness,
andlong-timeoutcomesofchildrensuppliedwithhearing
aids or cochlear implants independent from newborn
hearing screening. A two-step TEOAE test strategy as de-
scribed above was chosen.
InthecostcalculationscostsofTEOAE-testsandoffurther
diagnosticprocedureswereincluded.Becauseofthelack
of outcome and cost data, costs for medical treatment
and education of children as well as indirect costs could
not be included.
"Universal screening" (U), "risk screening"(R), and "no
screening"(N)asdescribedaboveweredefinedasaltern-
ative strategies.
Predicted outcomes were defined as:
1. Number of true positively detected cases of connatal
hearing disorder at 6 months
2. Number of "detected child months" at 6, 12, and 120
months
3. Costs per 100,000 screens
The outcome "Number of detected child months" (2.) is
described as the amount of months in the defined time
frameof6,12,or120monthsinwhichahearingdisorder
is known. For example, in a time horizon of 6 months a
childwithhearingdisorderdetectedatbirthisequivalent
to 6 detected child months. Detection with 4 months is
equivalent to 2 detected child months. This outcome
measurewaschoseninadditiontotheclassicaloutcome
"Number of cases detected" (1.) to underline the import-
ance of early detection. As cost-effectiveness outcomes
were calculated:
1. Costs per case of hearing disorder detected
2. Costs per detected child month
A health care system's perspective was chosen for the
cost calculations. To reflect the time dependance of
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subjectivepreferencescostsandoutcomeswerediscoun-
ted with a rate of 3%. A Markov-cycle length of 1 month
and a total time of 10 years were chosen for modelling.
Sensitivityanalyseswereperformedonrelevantparamet-
ers. All assumptions made and all parameters used are
shown in Table 1.
Results
Overall 39 economic publications on newborn hearing
screening were found. Because of a lack of transparent
cost data 19 publications were excluded. For further cal-
culations 20 publications remained: 16 journal articles,
threehealthtechnologyassessmentreports[4],[3],[19]
and one conference abstract. A series of three publica-
tions [20], [21], [22] reporting the results of the same
studywasconsideredasone.Overall15differentprimary
studies on newborn hearing screening with economic
components were included. For references please see
Table 2.
In general most of the economic publications showed a
relatively poor methodological quality according to inter-
nationalrecommendationforeconomicevaluationstudies
of health care programmes [23], [24], [25]. Only one
single study included costs of treatment and education
andchoseatimehorizonofmorethanoneyear.Thecost
calculationswerenottransparent,referencesforresource
uses and valuation as well as the perspective of the cal-
culation often remained unclear.
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Besidestheinterventioncostsforthescreeningtestitself
most of the studies limited the calculation to the costs
for tracking and further diagnostic of hearing disorders.
One study included the costs for implementation of the
screening programme. The costs for further medical
treatment of detected cases and special education were
included in one study. None of the studies considered
other direct non-medical costs or indirect costs. Also no
studies with utility measures or health related quality of
life were found (see also Table 2).
Thedifferentstudiesdidnotuseorcalculatesimilarsingle
item costs. After adjustment to € of 1999 the costs for
the same test showed an up to five time range regarding
the costs for screening tests, tracking and further dia-
gnostic, e.g. the test costs for a two-step TEOAE-ABR-
screen varied from 7.76€ to 26.88€. The highest single
item costs with more than 500,000€ were calculated for
long-time treatment and special education of children
with hearing disorders. In contrast to the importance of
the long-time outcome these costs were only included in
one study.
As all total costs presented in the different studies were
basedonsingleitembottom-upcostcalculationsthetotal
costsperscreenedchildandthecostspercasedetected
also showed a wide range. Table 2shows the results of
all included studies. If only recent publications and com-
parablesettingsandcalculationmethodsareconsidered,
the range can be narrowed to about 7-36€ per screened
child and 3,000-13,000€ per case detected. None of
these calculations included the costs or savings for long-
time treatment or education. There was no systematic
difference or trend towards a definite test-method.
Markov Model
Graph 1 shows the structure of the Markov model. All
childrenbegininthestartingstate"statusunknown"and
end up in one of the absorbing states "detected hearing
disorder" or "healthy, confirmed by diagnostic". The chil-
drenarescreenedwithacertainprobability.Thisprobab-
ility is 1.0 in strategy U (universal screening), according
totheprevalenceofatleastoneriskfactor0.2instrategy
R (risk screening) and 0.0 in strategy N (no screening).
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Further diagnostic procedures are performed in all
screening positive children. The children with hearing
disorders, who were not screened, are detected with a
"natural" detection rate, based on an empirical function
taken from the register of hearing disorders of the area
of Munich. Concerning the extent of a non-systematic
screening this area is considered as representative for
Germany. Therefore, strategy N does not represent a
situation without any screening at all but without a sys-
tematic screening.
Forthecalculationpresentedhereatwo-stepTEOAE-test
strategy was chosen. According to the specific sensitivity
and specificity of a two-step TEOAE-screening some chil-
dren are screening positive but healthy, some are
screening negative with undetected hearing disorder. A
drop out either at screening (10%) or at follow up after
positive screening test (20%) was included in the model
calculation.
With the assumed prevalence of 0.15 % in a cohort of
100,000 newborns 150 cases of connatal hearing dis-
order are present. At 6 months of life with a universal
screening strategy 108 cases (72%) are detected, with
a risk screening 64 (43%), without regular screening 20
(13%). Out of possible 900 detected child months with a
universal screening 630 months, with a risk screening
354 months and without screening 78 detected child
months were achieved.
The costs for screening 100,000 newborns using TEOAE
are calculated with about 2.0 Mio.€ for a universal
screening, 1.0 Mio.€ for screening of risk groups. The
costs for a strategy without regular screening were 0.6
Mio.€. This leads to costs per newborn of 20€ (U), 10€
(R) respectively 6€ (N). The costs per case of connatal
hearing disorder detected were calculated with 13,395€
(U), 6,715€ (R) and 4,125€ (N) (see also Table 3).
Sensitivity analyses of all relevant parameters and as-
sumptions were performed. Similar for all strategies the
strongest influence on outcomes was seen if prevalence
was varied. The variation of discount rate had little influ-
ence; the model was insensitive to test parameters
(sensitivityandspecificity)andlosstofollowup.Thecosts
were strongly influenced by variation of test costs, test
parameters especially the number of false test positives,
and the probability to be detected without screening.
Prevalence and discount rate did not affect the costs.
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Discussion
As part of a German interdisciplinary health technology
assessment project the economic consequences of
newborn hearing screening were investigated. In a de-
tailed literature search overall nearly 800 publications
dealing with hearing screening were found. Despite this
relativelylargenumberonly15studieswithowneconomic
calculations were detected.
Possibly also due to the different methodological ap-
proaches the costs per screening test and the costs per
casedetectedshowed-althoughadjustedandstandard-
ised to one currency and one year - a wide range without
a clear tendency to a definite test method.
The results of the published studies are insufficient to
answer the policy question regarding the economic con-
sequences in a sense of costs and cost-effectiveness of
different strategies for detection of connatal hearing
disorders.Thereisalackofconvincingstudiespresenting
results on a high level of evidence according to recom-
mendations of evidence based medicine and the need
for further research, especially randomised controlled
trials with a sufficient follow up, must be underlined.
The results of the assessment of the studies on the
medical effectiveness of newborn hearing screening are
presented in detail elsewhere. Most of the authors con-
clude from the results of their studies that a newborn
hearing screening should be recommended, although
there is an ongoing discussion if the present scientific
evidence can be considered as sufficient concerning the
maximumageofdiagnosisandtreatment[26],[27],[28],
[29].
To estimate the costs and outcomes of newborn hearing
screening a Markov model was designed. The model
presented here considers the aspect that, on one hand
all cases of connatal hearing disorders are detected
sooner or later, but on the other hand they should be
diagnosed as early as possible. Therefore in addition to
the outcome "number of cases detected by screening",
whichwasusedinallnewbornhearingscreeningstudies
found, we included the date of detection in our outcome
measure "detected child months".
Ontheoutcomesideexpressedinthenumberofdetected
cases and the number of detected child months the
model shows clear advantages for newborn hearing
screeningcomparedtonoregularscreening.Atthecrucial
date of 6 months without screening only 9% of the cases
are detected, with a screening of children with one or
moreriskfactorsthedetectionrateis40%,withauniver-
sal screening about 70%. A universal screening strategy
shows a higher rate of cases detected in time, and a
percentage of 40% detected with a risk screening does
not seem to be sufficient in considering the importance
of early diagnosis and treatment. Combining the men-
tioned advantages in medical outcome with still accept-
able and reasonable costs a universal hearing screening
is recommended.
We chose a two-step TEOAE-strategy for the model calcu-
lation presented here, but the model could be easily ad-
justed for other test strategies.
Thecost-effectivenessratiosarenotdirectlycomparable
tothoseofotherhealthcaretechnologies.Butwithcosts
per case detected of 14,000€ a universal screening
strategy seems to be reasonable if the lifelong benefits
are taken into account. If it is assumed in a conservative
calculation that half of the children benefit from earlier
detection and their quality of life improves by 10% over
50years,2.5QALYsaregained.Basedonourcostcalcu-
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possible utility measure for the comparison of different
health care strategies, would be less than 10,000€.
Because of the lack of literature data on health care re-
source use and the percentage of children, who are able
to visit a regular school after treatment with hearing aid
or cochlea implant - the existing studies on cochlea im-
plantation used a different population only of children
with severe hearing disorders - the cost calculations are
incomplete. Any savings connected to a better outcome
because of an earlier detection and treatment were not
included. If these savings as well as indirect costs e.g.
estimated as the avoided loss of income due to hearing
disorders, would be included in the calculation, there
might well be an overcompensation of screening costs.
Further studies will have to answer these questions.
Nevertheless,thepresentdataonmedicalandeconomic
outcomes suggest a recommendation of a universal
hearing screening with TEOAE or other test strategies.
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